Primary amyloidosis (AL) as a cause of nephrotic syndrome

Acta Clinica Belgica

Volumn 60, Issue 2, 2005, Pages 94-97

  Bataille, Yoann ^a,b   Bovy, C ^a,b   Lancellotti, P ^a,b   Melchior, V ^a,b   Delbecque, K ^a,b   Beguin, Y ^a,b   Krzesinski, J M ^a,b  

^a Department of Nephrology and Hypertension ^*

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Amyloidosis; Autologous stem cell transplantation; Nephrotic syndrome

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID; FUROSEMIDE; PARAPROTEIN; PERINDOPRIL;

ADULT; AMYLOIDOSIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMAN; MALE; NEPHROTIC SYNDROME; PROGNOSIS; SYSTEMIC DISEASE; DISEASE COURSE; DOPPLER FLOWMETRY; FATALITY; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEEDLE BIOPSY;

AMYLOIDOSIS; BIOPSY, NEEDLE; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEPHROTIC SYNDROME; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER;

EID: 24044541038     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2005.017     Document Type: Article

References (9)

1. Falk RH, Comenzo RL, Skinner M .The systemic amyloidoses. N Engl J Med. 1997; 337: 898-909.
2. Pascali E. Diagnosis and treatment of primary amyloidosis. Critic Rev Oncol Hemato. 1995; 19: 149-81.
3. Merlini G, Bellotti V .Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349: 583-96.
4. Gertz MA, Li C-Y, Shirahama T et al. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Intern Med. 1988; 148: 929-33.
5. Abraham RS, Katzmann JA, Clark RJ et al. Quantitative analysis of serum free light chains, a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol.2003; 119:274-8.
6. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123i-labeled serum amyloid P component. N Engl J Med. 1990; 323: 508-13.
7. Rysava R, Merta M, Spicka I et al. Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients. Nephrol Dial Transplant; 2003, 18 (Suppl 5): v38-v40.
8. Martha S, Vaishali S, David C et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med; 2004, 140:85-93.
9. Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature; 2002, 417:254-59.